PDF(Pubmed)
Abstract：
UNASSIGNED: Radical cystectomy (RC) is historically considered the gold standard treatment for muscle invasive and high-risk non-muscle invasive bladder cancer. However, this technique leaves the majority of patients of both sexes with poor sexual and urinary function. Organ-sparing cystectomy (OSC) techniques are emerging as an alternative to the standard procedure to preserve these functions, without compromising the oncological outcomes. We present a systematic review and meta-analysis of the published literature.
UNASSIGNED: MEDLINE, Embase and Web of Science were systematically searched for eligible studies on 6 April 2021. Primary outcomes studied were both oncological outcomes, specifically overall recurrence, and functional outcomes, specifically sexual function, and daytime and nighttime continence. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated. The PROSPERO registration reference number was CRD42018118897.
UNASSIGNED: From 13 894 identified abstracts, 19 studies (1886 male and 305 female patients) were eligible for inclusion in this review. These studies included patients who underwent either whole prostate, prostate capsule, seminal vesicle, nerve, uterus, ovary, vagina and fallopian tube sparing techniques. Four studies included only female patients.Thirteen studies reported oncological outcomes, and overall recurrence rate was similar between the two groups (five studies; OR 0.73; 95% CI 0.38-1.40, p = 0.34). Thirteen studies reported on male sexual function. In men, OSC had significantly greater odds of retaining potency (five studies; OR 9.05; 95% CI 5.07-16.16, p < 0.00001). Fourteen studies (13 on males and 1 female) reported urinary outcomes. In men, OSC demonstrated greater odds of daytime (seven studies; OR 2.61; 95% CI 1.74 to 3.92, p < 0.00001) and nighttime continence (seven studies; OR 2.62; 95% CI 1.76 to 3.89, p < 0.00001).
UNASSIGNED: In carefully selected patients, OSC allows the potential to provide better sexual and urinary function without compromising oncological outcomes. There remains, however, a paucity of OSC studies in females. Further studies are required to make recommendations based on robust clinical evidence.
UNASSIGNED: MEDLINE, Embase and Web of Science were systematically searched for eligible studies on 6 April 2021. Primary outcomes studied were both oncological outcomes, specifically overall recurrence, and functional outcomes, specifically sexual function, and daytime and nighttime continence. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated. The PROSPERO registration reference number was CRD42018118897.
UNASSIGNED: From 13 894 identified abstracts, 19 studies (1886 male and 305 female patients) were eligible for inclusion in this review. These studies included patients who underwent either whole prostate, prostate capsule, seminal vesicle, nerve, uterus, ovary, vagina and fallopian tube sparing techniques. Four studies included only female patients.Thirteen studies reported oncological outcomes, and overall recurrence rate was similar between the two groups (five studies; OR 0.73; 95% CI 0.38-1.40, p = 0.34). Thirteen studies reported on male sexual function. In men, OSC had significantly greater odds of retaining potency (five studies; OR 9.05; 95% CI 5.07-16.16, p < 0.00001). Fourteen studies (13 on males and 1 female) reported urinary outcomes. In men, OSC demonstrated greater odds of daytime (seven studies; OR 2.61; 95% CI 1.74 to 3.92, p < 0.00001) and nighttime continence (seven studies; OR 2.62; 95% CI 1.76 to 3.89, p < 0.00001).
UNASSIGNED: In carefully selected patients, OSC allows the potential to provide better sexual and urinary function without compromising oncological outcomes. There remains, however, a paucity of OSC studies in females. Further studies are required to make recommendations based on robust clinical evidence.
摘要：
UNASSIGNED：根治性膀胱切除术（RC）历来被认为是治疗肌肉浸润性和高危非肌肉浸润性膀胱癌的黄金标准。然而,这种技术使大多数男女患者的性功能和泌尿功能较差。保留器官的膀胱切除术（OSC）技术正在成为保留这些功能的标准程序的替代方法。在不影响肿瘤结果的情况下。我们对已发表的文献进行了系统的综述和荟萃分析。
未经批准：MEDLINE，在2021年4月6日对Embase和WebofScience进行了系统搜索，以寻找合格的研究。研究的主要结果是肿瘤结果，特别是整体复发，和功能结果，特别是性功能，白天和夜间节制。计算具有95%置信区间(95%CI)的赔率比(OR)。PROSPERO注册参考号为CRD42018118897。
未经评估：从13894个确定的摘要中，19项研究（1886名男性和305名女性患者）符合纳入本综述的条件。这些研究包括接受了整个前列腺的患者，前列腺囊,精囊,神经,子宫,子房,阴道和输卵管保留技术。四项研究仅包括女性患者。13项研究报告了肿瘤结果，两组间的总复发率相似(5项研究;OR0.73;95%CI0.38-1.40,p=0.34).13项研究报道了男性性功能。在男人中，OSC具有显著更大的保留效力的几率(5项研究;OR9.05;95%CI5.07-16.16,p<0.00001)。14项研究（男性13项，女性1项）报告了泌尿结局。在男人中，OSC显示白天（7项研究；OR2.61;95％CI1.74至3.92，p<0.00001）和夜间节制（7项研究；OR2.62;95％CI1.76至3.89，p<0.00001）的几率更大。
未经证实：在精心挑选的患者中，OSC允许在不损害肿瘤结果的情况下提供更好的性功能和泌尿功能的潜力。仍然存在，然而,女性OSC研究很少。需要进一步的研究以基于可靠的临床证据提出建议。
未经批准：MEDLINE，
未经评估：从13894个确定的摘要中，
未经证实：在精心挑选的患者中，
